Department of Medicine, Cardiovascular Research Laboratories and Eli Broad Center for Regenerative Medicine and Stem Cell Research,David Geffen School of Medicine at UCLA, United States
Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):324-30. doi: 10.1016/j.addr.2011.01.013. Epub 2011 Mar 1.
The discovery of induced pluripotent stem cells (iPSC) has, in the short time since their discovery, revolutionized the field of stem cell biology. This technology allows the generation of a virtually unlimited supply of cells with pluripotent potential similar to that of embryonic stem cells (ESC). However, in contrast to ESC, iPSC are not subject to the same ethical concerns and can be easily generated from living individuals. For the first time, patient-specific iPSC can be generated and offer a supply of genetically identical cells that can be differentiated into all somatic cell types for potential use in regenerative therapies or drug screening and testing. As the techniques for generation of iPSC lines are constantly evolving, new uses for human iPSC are emerging from in-vitro disease modeling to high throughput drug discovery and screening. This technology promises to revolutionize the field of medicine and offers new hope for understanding and treatment of numerous diseases.
诱导多能干细胞(iPSC)的发现,自发现以来,在短短时间内彻底改变了干细胞生物学领域。这项技术允许生成具有类似于胚胎干细胞(ESC)的多能潜能的几乎无限数量的细胞。然而,与 ESC 不同的是,iPSC 不受相同的伦理问题的限制,并且可以很容易地从活体个体中产生。首次可以生成患者特异性 iPSC,并提供大量遗传上相同的细胞,这些细胞可以分化为所有体细胞类型,用于再生疗法或药物筛选和测试的潜在用途。随着 iPSC 系生成技术的不断发展,人类 iPSC 的新用途不断涌现,从体外疾病建模到高通量药物发现和筛选。这项技术有望彻底改变医学领域,并为许多疾病的理解和治疗带来新的希望。